[Federal Register Volume 62, Number 203 (Tuesday, October 21, 1997)]
[Notices]
[Page 54641]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-27864]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by contacting George Keller, 
Ph.D., Technology Licensing Specialist, at the Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057, 
ext. 246; fax: 301/402-0220; e-mail: [email protected]. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
the patent applications.

Diagnostic Reagents and Vaccines for Multiple Genotypes of 
Hepatitis C Virus

J Bukh, RH Miller, RH Purcell (NIAID)
Serial Nos. 08/466,601 and 08/468,570 filed 06 Jun 95 (DIV of U.S. 
Patent 5,514,539 issued 07 May 96)

    The invention describes the complete nucleotide and deduced amino 
acid sequences of the envelope 1 (E1) gene of 51 hepatitis C virus 
(HCV) isolates from around the world and the grouping of these isolates 
into twelve distinct HCV genotypes. More specifically, this invention 
relates to the oligonucleotides, peptides and recombinant proteins 
derived from the envelope 1 gene sequences of these isolates and to 
diagnostic methods and vaccines that employ these reagents.

Antigenic Protein of Borrelia Burgdorferi

WJ Simpson, TG Schwan (NIAID)
Serial No. 08/396,957 filed 01 Mar 95 (DIV of U.S. Patent 5,470,712 
issued 28 Nov 95)

    This patent application describes a 39 kDA protein (P39) that is 
species-specific and expressed by all North American and European B. 
burgdorferi isolates. The discovery includes the cloning and expression 
of the gene for P39 in E. coli and the use of P39 as a diagnostic 
antigen for the serodiagnosis of Lyme borreliosis. The P39 described in 
this invention report has been found not only to be species-specific, 
but reactive only with human Lyme borreliosis sera. This suggests that 
any patient's serum that is shown to react to P39, irrespective of the 
patient's clinical picture, can be diagnosed as having or having had 
Lyme borreliosis.

Versatile Reagent for Detecting Murine Leukemia Viruses

LH Evans, WJ Britt (NIAID)
Serial No. 08/046,352 filed 08 Apr 93

    Monoclonal antibodies directed at the proteins of murine leukemia 
viruses (MuLVS) have some value as immunological reagents, but differ 
greatly in their applicability. The kit described in this invention 
uses a monoclonal antibody designated 83A25, which identifies almost 
all ecotropic, xenotropic, polytropic, and amphotropic MuLVs. It can be 
used in a wide variety of procedures, including focal 
immunofluorescence assays on live or fixed monolayers, immunoblotting, 
immunoprecipitation, immunohistochemical, and flow cytometric 
procedures. This kit overcomes some of the problems associated with 
prior methods, which may not effectively precipitate proteins or react 
in immunoblots, are not capable of detecting MuLVs belonging to all 
classes with a single reagent, and may not efficiently neutralize all 
MuLVs.

    Dated: October 7, 1997.
Barbara M. McGarey, J.D.
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-27864 Filed 10-20-97; 8:45 am]
BILLING CODE 4140-01-M